logo-loader
viewParallax Health Sciences Inc.

Full interview: Parallax Health Sciences on an 'accelerated path' in its diagnostics division with new partnership

Parallax Health Sciences Inc (OTCMKTS:PRLX) Chief Technology Office Nathaniel Bradley tells Proactive its subsidiary Parallax Diagnostics Inc is distributing vitamin D supplements to coronavirus medical and clinical services workers through a partnership with CURE Pharmaceutical Holding Corp.

Bradley says CURE produces an oral thin film supplement that delivers a dose of vitamin D, improving the immune system. Bradly says Parallax is an on 'accelerated path' in its diagnostics division.

Quick facts: Parallax Health Sciences Inc.

Price: 0.02 USD

OTCQB:PRLX
Market: OTCQB
Market Cap: $5.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Parallax Health Sciences Inc. named herein, including the promotion by the Company of Parallax Health Sciences Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Parallax Health Sciences advancing its coronavirus detection...

Parallax Health Sciences Inc's (OTCMKTS:PRLX) Nathaniel Bradley tells Proactive the tech company is trying its hand at developing a low-cost rapid coronavirus test, through its wholly-owned subsidiary Parallax Diagnostics Inc. What's more, Bradley said the California-based company has made...

on 03/12/2020

2 min read